logo

For the Inventor, By the Inventor

Novi, MI, United States of America

Aloke K Dutta

USPTO Granted Patents = 17 

 

Average Co-Inventor Count = 1.0

ph-index = 2

Forward Citations = 13(Granted Patents)


Location History:

  • Novi, MI (US) (2006 - 2014)
  • Troy, MI (US) (2015 - 2022)

Company Filing History:

goldMedal17 out of 580 
 
Wayne State University
 patents

Years Active: 2006-2022

Loading Chart...
Loading Chart...
17 patents (USPTO):Explore Patents
1. 11285147 - Neuroprotective agents for treatment of neurodegenerative diseases (2022-03-29),
2. 10874669 - Neuroprotective agents for treatment of neurodegenerative diseases (2020-12-29),
3. 10125127 - Neuroprotective agents for treatment of neurodegenerative diseases (2018-11-13),
4. 9458124 - Substituted pyran derivatives (2016-10-04),
5. 9034877 - Bifunctional/polyfunctional dopamine D2/D3 agonist as neuroprotective agents for treatment of neurodegenerative diseases (2015-05-19),
6. 8937189 - Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives (2015-01-20),
7. 8841464 - Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives (2014-09-23),
8. 8519159 - Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-OL and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-OL analogues, and novel 3,6-disubstituted pyran derivatives (2013-08-27),
9. 8227604 - Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity (2012-07-24),
10. 8211916 - N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith (2012-07-03),
11. 8017791 - Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel, 3,6-disubstituted pyran derivatives (2011-09-13),
12. 7915433 - Tri-substituted 2-benzhydryl 5-benzlamino-tetrahydro-pyran-4-OL and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-OL analogues, and novel 3,6 disubstituted pyran derivatives (2011-03-29),
13. 7723519 - Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity (2010-05-25),
14. 7595331 - N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith (2009-09-29),
15. 7049337 - Derivatives of 2-aminotetralins and pharmaceutical analogs thereof exhibiting differential CNS receptor activity and behavior (2006-05-23),

Title: The Innovative Journey of Aloke K Dutta

Introduction: Aloke K Dutta, a pioneering inventor based in Novi, MI (US), has made significant contributions to the field of technology through his inventive spirit and dedication.

Latest Patents: Aloke K Dutta holds several patents in various technological domains, showcasing his versatility and creativity in innovation.

Career Highlights: With a career spanning over two decades, Aloke K Dutta has worked tirelessly to bring his ideas to life, revolutionizing the industry with his groundbreaking inventions. His commitment to excellence and passion for innovation have earned him recognition as a leading figure in the field.

Collaborations: Throughout his career, Aloke K Dutta has collaborated with top industry experts, research institutions, and universities to further his research and bring his inventions to the market. His ability to work effectively in multidisciplinary teams has led to successful partnerships and groundbreaking innovations.

Conclusion: Aloke K Dutta's journey as an inventor exemplifies the power of creativity, perseverance, and collaboration in driving technological advancements. His innovative spirit continues to inspire future generations of inventors to push the boundaries of what is possible in the world of technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…